Up-and-down Sequential Method in Determining Median Effective Effect-Site Concentration (EC50) of Remifentanil Required for Inhibiting Intubation-Induced Hemodynamic Responses in Patients with Parkinson's Disease During Target-Controlled Infusion of Propofol

许小平,王嘉锋,余喜亚,杨涛,李金宝,邓小明

DOI: https://doi.org/10.3724/sp.j.1008.2013.00868

2013-01-01

Abstract:Objective To determine the median effective effect-site concentration (EC50) of remifentanil required to inhibit hemodynamic responses induced by intubation during target-controlled infusion (TCI) of propofol in patients with Parkinson's disease.Methods A 1 ∶ 1 matched case control design was used in the study.Thirty-one ASA Ⅰ-Ⅱ patients with Parkinson's disease undergoing general anesthesia were enrolled,and 31 controls were the hospitalized patients with nonParkinson's disease during the same period (same sex,age ±-3 years old).A TCI of propofol was used to maintain a predetermined effect-site concentration of 3 μg/mL.The target effect site concentration of remifentanil was determined by a modified Dixon's up-and-down sequential method.The initial target effect-site concentrations of remifentanil were 3 ng/mL in the two groups and the increments or decrements between the two consecutive patients were 0.2 ng/mL.A positive response meant that either the heart rate or the systolic blood pressure was elevated by 15％ in the first 5 min after intubation.Results There was no patient showed sign of muscle rigidity,and no patient recalled awareness during anesthesia in postoperative follow-up.During TCI of propofol,the EC50 of remifentanil required for inhibiting intubation induced hemodynamic responses for patients with Parkinson's disease was 2.20 ng/mL (95 ％ confidence interval:1.86-2.60 ng/mL).And the EC50 of remifentanil required for control group was significantly higher than for patients with Parkinson's disease (2.93 ng/mL,95％ confidence interval:2.72-3.15 ng/mL).Conclusion When combined with TCI of propofol (target effect site concentration 3 μg/mL),the EC50 of remifentanil required for inhibiting intubation induced hemodynamic responses for patients with Parkinson's disease is less than that for non-Parkinson's disease.